Contezolid acefosamil - MicuRx Pharmaceuticals
Alternative Names: MRX 4 - MicuRx PharmaceuticalsLatest Information Update: 28 Jan 2025
At a glance
- Originator MicuRx Pharmaceuticals
- Class Antibacterials; Oxazolidinones; Skin disorder therapies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic foot; Skin and soft tissue infections
- No development reported Gram-positive infections
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Gram-positive-infections(In volunteers) in China (IV)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Gram-positive-infections(In volunteers) in China (PO)
- 29 Nov 2024 Phase-III clinical trials in Skin and soft tissue infections in China (IV), prior to November 2024